IntelliPlex®
Single Gene Mutation Kits

KRAS, NRAS, BRAF and PIK3CA



The Genetic Profile Toward Target Therapy

High Sensitivity

KRAS: 0.36~3.07% LoD

NRAS: 0.14~6.48% LoD

BRAF: 0.29~1.57% LoD

PIK3CA: 0.2~2.08% LoD

Flexible Testing Combinations

27 of KRAS Mutations

33 of NRAS Mutations

7 of BRAF Mutations

17 of PIK3CA Mutations

Quick Turnaround

<5.5 hr from sample to report

Low Sample Input

DNA: ≥10ng

Molecular Landscape on Colorectal Cancer (CRC)

Frequency of KRAS and NRAS Mutations Beyond KRAS Exon 2 in the Updated Analysis of the PRIME Study

PRIME = Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy. Data from Douillard et al. N Engl J Med. 2013.[36] NT = not tested.





PLEXBIO™

Comparison Data between IntelliPlex® Single Gene Mutation Kits and Gold Standard- Sanger Sequencing

KRAS		Sanger Sequencing	
		Mutation Detected	Mutation Not Detected
IntelliPlex® KRAS Plus Mutation Kit	Mutation Detected	15	1
	Mutation Not Detected	2	25
	Positive agreement : 88%; Negative agreement : 96%; Overall agreement : 93%		

NRAS		Sanger Sequencing	
		Mutation Detected	Mutation Not Detected
IntelliPlex® NRAS Mutation Kit	Mutation Detected	3	0
	Mutation Not Detected	0	44
	Positive agreement : 100%; Negative agreement : 100%; Overall agreement : 100%		

BRAF		Sanger Sequencing	
		Mutation Detected	Mutation Not Detected
IntelliPlex® BRAF V600 Mutation Kit	Mutation Detected	5	1
	Mutation Not Detected	0	54
	Positive agreement : 100%; Negative agreement : 98.18%; Overall agreement : 98.33%		

Tailoring Individual Healthcare at Each Step Through Personal Genetic Profile



Genetic Analysis

Therapy Selection

Response Monitoring

Recurrence Monitoring

Website

LinkedIn

PLEXBIO™

CONTACT US

+886-2-2627-5878 marketing@plexbio.com www.plexbio.com

RUO STATEMENT For Research Use Only. Not for diagnostic procedures.